1. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocrine reviews. 2004;25(2):235-275.
2. Naor Z, Huhtaniemi I. Interactions of the GnRH receptor with heterotrimeric G proteins. Frontiers in neuroendocrinology. 2013;34(2):88-94.
3. Reinhart J, Mertz LM, Catt KJ. Molecular cloning and expression of cDNA encoding the murine gonadotropin-releasing hormone receptor. The Journal of biological chemistry. 1992;267(30):21281-21284.
4. Tsutsumi M, Zhou W, Millar RP, Mellon PL, Roberts JL, Flanagan CA, Dong K, Gillo B, Sealfon SC. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Molecular endocrinology (Baltimore, Md). 1992;6(7):1163-1169.
5. Hawes BE, Barnes S, Conn PM. Cholera toxin and pertussis toxin provoke differential effects on luteinizing hormone release, inositol phosphate production, and gonadotropin-releasing hormone (GnRH) receptor binding in the gonadotrope: evidence for multiple guanyl nucleotide binding proteins in GnRH action. Endocrinology. 1993;132(5):2124-2130.
6. Stanislaus D, Ponder S, Ji TH, Conn PM. Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins. Biology of reproduction. 1998;59(3):579-586.
7. Hille B, Tse A, Tse FW, Almers W. Calcium oscillations and exocytosis in pituitary gonadotropes. Annals of the New York Academy of Sciences. 1994;710:261-270.
8. Voliotis M, Garner KL, Alobaid H, Tsaneva-Atanasova K, McArdle CA. Gonadotropin-releasing hormone signaling: An information theoretic approach. Mol Cell Endocrinol. 2018;463:106-115.
9. Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, Schultz G, Gudermann T. Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. The Journal of biological chemistry. 2000;275(13):9193-9200.
10. Krsmanovic LZ, Mores N, Navarro CE, Arora KK, Catt KJ. An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2969-2974.
11. Kang SK, Choi KC, Yang HS, Leung PC. Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. Endocrine-related cancer. 2003;10(2):169-177.
12. Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 1994;106(1-2):145-149.
13. Bono AV, Salvadore M, Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Analytical and quantitative cytology and histology. 2002;24(4):221-227.
14. Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000;159(1-2):37-43.
15. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer research. 2004;64(20):7533-7544.
16. Kraus S, Levy G, Hanoch T, Naor Z, Seger R. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer research. 2004;64(16):5736-5744.
17. Angelucci C, Iacopino F, Lama G, Capucci S, Zelano G, Boca M, Pistilli A, Sica G. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer research. 2004;24(5a):2729-2738.
18. Kraus S, Naor Z, Seger R. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer letters. 2006;234(2):109-123.
19. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology. 1999;140(11):5250-5256.
20. Dondi D, Moretti RM, Montagnani Marelli M, Pratesi G, Polizzi D, Milani M, Motta M, Limonta P. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. International journal of cancer. 1998;76(4):506-511.
21. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert opinion on investigational drugs. 2009;18(5):687-694.
22. Kim JW, Yadav DK, Kim SJ, Lee MY, Park JM, Kim BS, Kim MH, Park HG, Kang KW. Anti-cancer effect of GV1001 for prostate cancer; function as a ligand of GnRHR. Endocrine-related cancer. 2018.
23. Collado B, Carmena MJ, Cortes J, Schally AV, Prieto JC. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary. International journal of oncology. 2004;24(3):725-730.
24. Salvador A, Garcia-Paramio MP, Sanchez-Chapado M, Carmena MJ, Prieto JC. Effects of the luteinising hormone-releasing hormone (LH-RH) agonist leuprolide on adenylyl cyclase regulation through G-protein coupled receptors in rat ventral prostate. European journal of cancer (Oxford, England : 1990). 2001;37(5):641-648.
25. Garcia-Fernandez MO, Solano RM, Sanchez-Chapado M, Ruiz-Villaespesa A, Prieto JC, Carmena MJ. Low expression of Galpha protein subunits in human prostate cancer. The Journal of urology. 2001;166(6):2512-2517.
26. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, Jouffre N, Huynen MA, Bork P. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic acids research. 2005;33(Database issue):D433-437.
27. Sutherland RM, McCredie JA, Inch WR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. Journal of the National Cancer Institute. 1971;46(1):113-120.
28. Jeon S, Lee HS, Lee GY, Park G, Kim TM, Shin J, Lee C, Oh IH. Shift of EMT gradient in 3D spheroid MSCs for activation of mesenchymal niche function. Sci Rep. 2017;7(1):6859.
29. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer research. 2012;72(2):527-536.
30. Chen WY, Tsai YC, Siu MK, Yeh HL, Chen CL, Yin JJ, Huang J, Liu YN. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. Oncogene. 2017;36(45):6213-6224.
31. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, Chang C. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO molecular medicine. 2013;5(9):1383-1401.
32. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine reviews. 2007;28(7):778-808.
33. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997;43(1):69-77.
34. Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Molecular and cellular biology. 2012;32(2):399-414.
35. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nature communications. 2015;6:8126.
36. Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes & development. 2016;30(1):1-17.
37. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & development. 2007;21(21):2747-2761.
38. Imai A, Horibe S, Takagi A, Tamaya T. Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. American journal of obstetrics and gynecology. 1997;176(2):371-376.
39. Grundker C, Volker P, Emons G. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology. 2001;142(6):2369-2380.
40. White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K. Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology. 2008;88(2):67-79.
41. Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T. Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. The Journal of clinical endocrinology and metabolism. 1996;81(9):3249-3253.
42. Emons G, Muller V, Ortmann O, Schulz KD. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. The Journal of steroid biochemistry and molecular biology. 1998;65(1-6):199-206.
43. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. The Journal of clinical endocrinology and metabolism. 2009;94(5):1761-1767.
44. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacology & therapeutics. 2013;140(3):223-238.
45. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature reviews Cancer. 2002;2(5):389-396.
46. El-Sayed IY, Daher A, Destouches D, Firlej V, Kostallari E, Maille P, Huet E, Haidar-Ahmad N, Jenster G, de la Taille A, Abou Merhi R, Terry S, Vacherot F. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. Cancer letters. 2017;410:100-111.
47. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. Journal of carcinogenesis. 2011;10:20.
48. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Molecular cancer therapeutics. 2009;8(3):665-671.
49. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461(7263):495-500.
50. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer cell. 2006;9(5):367-378.
51. Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer research. 2008;68(21):8770-8778.
52. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO reports. 2014;15(6):642-656.
53. Pan D. The hippo signaling pathway in development and cancer. Developmental cell. 2010;19(4):491-505.
54. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114(4):445-456.
55. Janse van Rensburg HJ, Yang X. The roles of the Hippo pathway in cancer metastasis. Cellular signalling. 2016;28(11):1761-1772.
56. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature reviews Drug discovery. 2014;13(1):63-79.
57. Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, Dai Y, Liu S, Yang CT, Li H, Hu B, Jablons DM, You L. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget. 2016;7(32):51922-51933.
58. Thoma C. Prostate cancer: Targetable YAP1-AR interaction key to disease progression. Nature reviews Urology. 2015;12(11):596.
59. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, Guan KL. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780-791.